The brain–skin connection: role of psychosocial factors and neuropeptides in psoriasis

References

• Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J. Leukoc. Biol.79(6), 1093–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat. Rev. Immunol.5(3), 243–251 (2005).
   PubMed Web of Science ®Google Scholar
• Maes M, Song C, Lin A et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine10, 313–318 (1998).
   PubMed Web of Science ®Google Scholar
• Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl Acad. Sci. USA100(15), 9090–9095 (2003).
   PubMed Web of Science ®Google Scholar
• Kavelaars A, Heijnen CJ. Stress, genetics, and immunity. Brain Behav. Immun.20(4), 313–316 (2006).
   PubMed Web of Science ®Google Scholar
• Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun.21(4), 374–383 (2007).
   PubMed Web of Science ®Google Scholar
• Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience135(3), 659–678 (2005).
   PubMed Web of Science ®Google Scholar
• Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr. Pharm. Des.11(8), 963–972 (2005).
   PubMed Web of Science ®Google Scholar
• Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry29(2), 201–217 (2005).
   PubMed Web of Science ®Google Scholar
• Pace TW, Mletzko TC, Alagbe O et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry163(9), 1630–1633 (2006).
   PubMed Web of Science ®Google Scholar
• Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci.9(1), 46–56 (2008).
   PubMed Web of Science ®Google Scholar
• Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-α in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res.105(1–2), 45–55 (2001).
   PubMed Web of Science ®Google Scholar
• Maes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-α-based immunotherapy in patients with hepatitis C. Acta Psychiatr. Scand.109(2), 126–131 (2004).
   PubMed Web of Science ®Google Scholar
• Marsland AL, Prather AA, Petersen KL, Cohen S, Manuck SB. Antagonistic characteristics are positively associated with inflammatory markers independently of trait negative emotionality. Brain Behav. Immun.22(5), 753–761 (2008).
   PubMed Web of Science ®Google Scholar
• Chapman BP, Khan A, Harper M et al. Gender, race/ethnicity, personality, and interleukin-6 in urban primary care patients. Brain Behav. Immun.23(5), 636–642 (2009).
   PubMed Web of Science ®Google Scholar
• Karlamangla AS, Singer BH, McEwen BS, Rowe JW, Seeman TE. Allostatic load as a predictor of functional decline. MacArthur studies of successful aging. J. Clin. Epidemiol.55(7), 696–710 (2002).
   PubMed Web of Science ®Google Scholar
• Gruenewald TL, Seeman TE, Ryff CD, Karlamangla AS, Singer BH. Combinations of biomarkers predictive of later life mortality. Proc. Natl Acad. Sci. USA103(38), 14158–14163 (2006).
   PubMed Web of Science ®Google Scholar
• Karlamangla AS, Singer BH, Seeman TE. Reduction in allostatic load in older adults is associated with lower all-cause mortality risk: MacArthur studies of successful aging. Psychosom. Med.68(3), 500–507 (2006).
   PubMed Web of Science ®Google Scholar
• Valdimarsson H. The genetic basis of psoriasis. Clin. Dermatol.25(6), 563–567 (2007).
   PubMed Web of Science ®Google Scholar
• van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr. Opin Allergy Clin. Immunol.7(5), 374–381 (2007).
   PubMed Web of Science ®Google Scholar
• Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(h)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature445(7128), 648–651 (2007).
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol.128(5), 1207–1211 (2008).
   PubMed Web of Science ®Google Scholar
• Korver JE, van Duijnhoven MW, Pasch MC, van Erp PE, van de Kerkhof PC. Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. Br. J. Dermatol.155(4), 688–694 (2006).
   PubMed Web of Science ®Google Scholar
• Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp. Dermatol.13(2), 106–112 (2004).
   PubMed Web of Science ®Google Scholar
• Kourosh AS, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Ther. Lett.13(1), 1–5 (2008).
   PubMedGoogle Scholar
• Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J. Dermatolog. Treat.19(1), 5–21 (2008).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J. Drugs Dermatol.7(6), 563–572 (2008).
   PubMed Web of Science ®Google Scholar
• Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr. Opin Rheumatol.20(4), 416–422 (2008).
   PubMed Web of Science ®Google Scholar
• Urpe M, Buggiani G, Lotti T. Stress and psychoneuroimmunologic factors in dermatology. Dermatol. Clin.23(4), 609–617 (2005).
   PubMed Web of Science ®Google Scholar
• Halevy S, Livni E. β-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism. J. Am. Acad. Dermatol.29(3), 504–505 (1993).
   PubMed Web of Science ®Google Scholar
• Steinkraus V, Steinfath M, Stove L, Korner C, Abeck D, Mensing H. β-adrenergic receptors in psoriasis: evidence for down-regulation in lesional skin. Arch. Dermatol. Res.285(5), 300–304 (1993).
   PubMed Web of Science ®Google Scholar
• Farber EM, Lanigan SW, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis. Int. J. Dermatol.29(6), 418–420 (1990).
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Farber EM, Raychaudhuri SK. Role of nerve growth factor in RANTES expression by keratinocytes. Acta Derm. Venereol.80(4), 247–250 (2000).
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall L. Psoriasis: a stress-related disease. Cutis51(5), 322–326 (1993).
   PubMed Web of Science ®Google Scholar
• Farber EM, Nickoloff BJ, Recht B, Fraki JE. Stress, symmetry, and psoriasis: possible role of neuropeptides. J. Am. Acad. Dermatol.14(2 Pt 1), 305–311 (1986).
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Schroder JM, von den DP et al. Is psoriasis a T-cell disease? Exp. Dermatol.9(5), 359–375 (2000).
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Jiang WY, Smoller BR, Farber EM. Nerve growth factor and its receptor system in psoriasis. Br. J. Dermatol.143(1), 198–200 (2000).
   PubMed Web of Science ®Google Scholar
• Aloe L, Alleva E, Fiore M. Stress and nerve growth factor: findings in animal models and humans. Pharmacol. Biochem. Behav.73(1), 159–166 (2002).
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am. J. Clin. Dermatol.6(6), 383–392 (2005).
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J. Psychosom. Res.50(1), 11–15 (2001).
   PubMed Web of Science ®Google Scholar
• Hughes JE, Barraclough BM, Hamblin LG, White JE. Psychiatric symptoms in dermatology patients. Br. J. Psychiatry143, 51–54 (1983).
   PubMed Web of Science ®Google Scholar
• Fortune D, Richards HL, Griffiths CE, Main CJ. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol. Clin.23, 681–693 (2005).
   PubMed Web of Science ®Google Scholar
• Naldi L, Peli L, Parazzini F, Carrel CF. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J. Am. Acad. Dermatol.44(3), 433–438 (2001).
   PubMed Web of Science ®Google Scholar
• Fortune DG, Richards HL, Griffiths CE, Main CJ. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br. J. Clin. Psychol.41(Pt 2), 157–174 (2002).
   PubMed Web of Science ®Google Scholar
• Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J. Invest. Dermatol.126(8), 1697–1704 (2006).
   PubMed Web of Science ®Google Scholar
• Harvima IT, Viinamaki H, Naukkarinen A et al. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother. Psychosom.60(3–4), 168–176 (1993).
   PubMed Web of Science ®Google Scholar
• Joachim RA, Kuhlmei A, Dinh QT et al. Neuronal plasticity of the ‘brain–skin connection’: stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways. J. Mol. Med.85(12), 1369–1378 (2007).
   PubMed Web of Science ®Google Scholar
• Tausk F, Whitmore SE. A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother. Psychosom.68(4), 221–225 (1999).
   PubMed Web of Science ®Google Scholar
• Shenefelt PD. Biofeedback, cognitive-behavioral methods, and hypnosis in dermatology: is it all in your mind? Dermatol. Ther.16(2), 114–122 (2003).
   PubMedGoogle Scholar
• Fortune DG, Richards HL, Griffiths CE, Main CJ. Targeting cognitive-behaviour therapy to patients’ implicit model of psoriasis: results from a patient preference controlled trial. Br. J. Clin. Psychol.43(Pt 1), 65–82 (2004).
   PubMed Web of Science ®Google Scholar
• Zachariae R, Oster H, Bjerring P, Kragballe K. Effects of psychologic intervention on psoriasis: a preliminary report. J. Am. Acad. Dermatol.34(6), 1008–1015 (1996).
   PubMed Web of Science ®Google Scholar
• Kabat-Zinn J, Wheeler E, Light T et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom. Med.60(5), 625–632 (1998).
   PubMed Web of Science ®Google Scholar